In Mirum’s trial, volixibat delivered statistically significant and clinically meaningful reductions in cholestatic pruritus or an intense, often debilitating itching caused by liver diseases. ・The ...

New York, New York--(Newsfile Corp. - August 7, 2025) - OS Therapies (NYSE American: OSTX) ("OS Therapies" or "the Company"), a clinical-stage immunotherapy and Antibody Drug Conjugate (ADC) ...

Global warming has accelerated since 2015, according to a new study by the Potsdam Institute for Climate Impact Research (PIK). After accounting for known natural influences on global temperature, the ...

InVera Medical announced 12-month results from its pilot clinical study of the InVera infusion device for the treatment of ...

Analysis demonstrates statistically significant reduction in the severity of surgical wound infections, with potential to ...

aTyr Pharma is a small-cap biotech focused on Efzofitimod for interstitial lung disease (ILD), a group of lung-scarring diseases. In 2021, the company completed a phase 1b/2a trial in pulmonary ...